Abstract: The present disclosure relates to an isolated anti-FcRN antibody, which is an antibody binding to FcRN (stands for neonatal Fc receptor, also called FcRP, FcRB or Brambell receptor) that is a receptor with a high affinity for IgG or a fragment thereof, a method of preparing thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmunre diseases using the antibody. The FcRn-specific antibody according to the present disclosure binds to FcRn non-competitively with IgG to reduce serum pathogenic auto-antibody levels, and thus can be used for the treatment of autoimmune diseases.

Abstract: An electrolyte for a lithium secondary battery is disclosed herein. In some embodiments, an electrolyte includes a lithium salt present in a concentration of 1.6 M to 5 M, an oligomer mixture including a first oligomer containing a unit represented by Formula 1 and a second oligomer containing a unit represented by Formula 2, and an organic solvent.

Abstract: Disclosed are a novel monofunctional polyethylene glycol (PEG) and derivatives thereof. More particularly, one terminal of each of the monofunctional polyethylene glycol and derivatives thereof is modified with a tertiary alkoxy group.

Abstract: Disclosed are a novel monofunctional polyethylene glycol (PEG) and derivatives thereof. More particularly, one terminal of each of the monofunctional polyethylene glycol and derivatives thereof is modified with a tertiary alkoxy group.

Abstract: The present invention relates to a polyethylene glycol hydrogel injection, and, more particularly, to an injection to be administered into a joint (a synovial joint cavity) for the improvement of symptoms of arthritis by containing two separate buffer solutions, wherein a solution (1) contains a polyethylene glycol derivative with an electrophilic functional group and a buffer of pH 3.5 to 6, and a solution (2) contains a polyethylene glycol derivative with a nucleophilic functional group, hyaluronic acid, and a buffer of pH 7.5 to 11. The injection of the present invention is highly biocompatible and long-lasting in the joint, showing the efficacy of pain relief, cartilage protection, and inhibition of inflammation, thus offering the effective prevention and treatment of arthritis.

Abstract: Provided is a method of relieving, improving, preventing or treating xerostomia including applying an oral cavity composition including a polyethylene glycol (PEG) derivative whose reactor is modified to form a covalent bond with an epithelial cell of the oral cavity. An oral moisturizing effect and moisture persistency are increased and the method is effective against xerostomia due to aging or disease.

Abstract: Disclosed are peptides for inhibiting mdm2 (mouse double minute 2) and a pharmaceutical composition comprising the same.

Abstract: Disclosed are peptides for inhibiting mdm2 (mouse double minute 2) and a pharmaceutical composition comprising the same.

Abstract: The present invention provides a hair treatment composition comprising a multi-arm polyethylene glycol derivative (A) that contains two or more functional groups that may be covalently bound to amines, a hair treatment agent comprising the composition, and a method for using the same. Optionally, the composition may further comprise a polyethylene glycol derivative (B), a biocompatible polymer (C), or both, wherein the derivative (B) and polymer (C) each contains one or more functional groups that may react with the functional groups of the derivative (A).